Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average recommendation of “Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $43.00.

A number of research analysts recently commented on BCAX shares. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Stifel Nicolaus started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective on the stock. Rodman & Renshaw started coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective on the stock. TD Cowen assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. Finally, HC Wainwright assumed coverage on Bicara Therapeutics in a research note on Friday, December 6th. They set a “buy” rating and a $42.00 price target on the stock.

Bicara Therapeutics Stock Down 3.1 %

BCAX stock opened at $11.60 on Monday. The firm has a 50 day moving average of $17.08. Bicara Therapeutics has a 1 year low of $11.51 and a 1 year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). Equities research analysts predict that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Several hedge funds have recently modified their holdings of the stock. Spire Wealth Management acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at $31,000. SG Americas Securities LLC purchased a new position in Bicara Therapeutics in the fourth quarter valued at $147,000. Cinctive Capital Management LP purchased a new position in Bicara Therapeutics in the third quarter valued at $229,000. Barclays PLC purchased a new position in Bicara Therapeutics in the third quarter valued at $255,000. Finally, Jane Street Group LLC purchased a new position in Bicara Therapeutics in the third quarter valued at $309,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.